AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company currently has two products in its pipeline: MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients) and AZX1103, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. The company is headquartered in New York City, with scientific operations in Langlade, France. Source
No articles found.
Scottline helps healthcare organizations establish a secure, agile digital infrast...
Scottline helps healthcare organizations establ...
It was the middle of 2016 when we discovered that CBD could make a big difference ...
It was the middle of 2016 when we discovered th...
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing...
scPharmaceuticals is a clinical-stage pharmaceu...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.